Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remdesivir Shows Promising Results In Leaked Report But Doubts Remain

No Comparator Arm One Issue?

Executive Summary

Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.

You may also be interested in...



Apparent China Study Failure May Not Spell End For Remdesivir COVID-19 Role

Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.

Could Gilead Make A Profit From Remdesivir?

All being well, Gilead could gain emergency approval for remdesivir by early May - but arriving at a 'reasonable' price and devising rapid access programs will be a major challenge.

Coronavirus Update: Remedesivir China Trials Halted, Witty To Spearhead WHO's Vaccines Efforts

Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel